Julia-Tatjana Maul
Overview
Explore the profile of Julia-Tatjana Maul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haulrig M, Andersson A, Maul J, Xu J, Lwin S, Flohr C, et al.
Contact Dermatitis
. 2025 Mar;
PMID: 40045439
Background: Hand eczema (HE) is described as a common disease in Greenland, but studies on its epidemiology and severity are lacking. Objectives: To investigate the point prevalence and severity of...
2.
Sieborg J, Maul J, Wu J, Loft N, Skov L, Bryld L, et al.
Acta Derm Venereol
. 2025 Mar;
105:adv42572.
PMID: 40026110
Biosimilars are designed to be analogous to the biologic originators. However, comprehensive comparisons between biosimilars are limited and lacking for patients with psoriasis. This study's objective was to compare 1-year...
3.
Birkenmaier I, Maul J
J Eur Acad Dermatol Venereol
. 2025 Feb;
39(3):453-454.
PMID: 39996331
No abstract available.
4.
Benezeder T, Bordag N, Woltsche J, Falkensteiner K, Graier T, Schadelbauer E, et al.
J Allergy Clin Immunol
. 2025 Feb;
PMID: 39978684
Background: Due to similarities, the distinction between generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP) has been a matter of debate for a long time. Objectives: Our aim...
5.
Zhang D, Sieborg J, Nielsen V, Nymand L, Alinaghi F, Thyssen J, et al.
J Eur Acad Dermatol Venereol
. 2025 Feb;
PMID: 39945440
No abstract available.
6.
Lichtenberger R, Maul L, Birkenmaier I, Oyanguren I, Ak M, Heidemeyer K, et al.
Acta Derm Venereol
. 2025 Feb;
105:adv42296.
PMID: 39916484
Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in...
7.
Thaci D, Ohtsuki M, Maul J, Szegedi A, Luna P, Lynde C, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):381-394.
PMID: 39904971
Introduction: Risankizumab is approved for treating moderate-to-severe psoriasis. This interim analysis at 25 months evaluated the effectiveness of risankizumab compared with other approved biologics (OtherBios) among patients with moderate-to-severe psoriasis...
8.
Thein D, Maul J, Ribero S, Silverberg J, Egeberg A, Thyssen J
Contact Dermatitis
. 2025 Jan;
PMID: 39756812
Background: The epidemiology of chronic hand eczema (CHE) remains poorly examined. Objective: To investigate the prevalence of CHE in a general adult population and describe the characteristics of affected individuals....
9.
Peter J, Helfenstein F, Cerminara S, Maul J, Zehnder M, Jamiolkowski D, et al.
Acta Derm Venereol
. 2025 Jan;
105:adv41025.
PMID: 39749388
Pregnancy-associated changes in melanocytic nevi (MN), apart from size increase on the trunk, remain a topic of debate. We conducted the first prospective study to investigate dermoscopic changes in MN...
10.
Maul J, Ak M, Cerminara S, Steinmann S, Goessinger E, Darzina A, et al.
Acta Derm Venereol
. 2024 Nov;
104:adv40946.
PMID: 39601368
Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of...